Articles tagged with: Carfilzomib
This year’s American Society of Clinical Oncology (ASCO), which was held in Chicago, began on Friday and concluded on Tuesday.
Monday was the busiest day at the meeting with regard to myeloma research. It featured a session of oral presentations in the morning and a poster session in the afternoon.
This update summarizes the myeloma-related studies presented during the afternoon poster session, which was the final myeloma-related session of the meeting. An earlier article covered the findings from the oral presentations that were given in the morning.
Most of …
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.
Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that included eight talks about important new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.
This article summarizes the most important findings from Monday’s oral presentation session. A later article will cover the findings from the afternoon poster session.
The content in our daily updates is based …
This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.
Sunday started with a poster session in which important new research findings were summarized on posters displayed throughout a large conference hall.
The studies presented during the session were on a wide variety of myeloma-related topics, including new treatments being developed for myeloma, currently used regimens, smoldering multiple myeloma, and findings on initial therapy.
Some of the posters included preliminary results from ongoing clinical trials. Others described …
In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.
In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.
According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.
Some Historical Perspective
In their review article, Drs. …
A subanalysis of recent clinical trial results shows good response rates for single-agent Kyprolis in heavily pretreated multiple myeloma patients with high-risk chromosomal abnormalities.
Specifically, the investigators found that the response rates for patients with high-risk chromosomal abnormalities were similar to those for patients without high-risk chromosomal abnormalities.
However, the researchers also found that response duration and overall survival remained significantly lower in patients with high-risk chromosomal abnormalities.
Nevertheless, the researchers describe the results as encouraging, and they suggest that treatment with Kyprolis (carfilzomib) may be beneficial for patients …